Endocrinology
Insulin glulisine
Brand: Apidra®
PBAC's latest decision on Insulin glulisine: Recommended (2007). Considered for treatment of Type 1 and Type 2 diabetes mellitus.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2007 → 2007
Eligible population
patients with Type 1 or Type 2 diabetes requiring a combination of basal and prandial insulin to maintain appropriate glycaemic control
- Therapy area
- Endocrinology
- Evidence base
- RCT, Meta-analysis
- Primary endpoint
- HbA1c reduction
- Key trials
- Study 3001, Study 3002, Study 3005, Meta-analysis 1, Meta-analysis 2
- Comparator
- insulin lispro
- Economic model
- Cost-minimisation
- ICER note
- Cost-minimisation analysis used; no ICER calculated
Open on full dashboard →